Pharmacokinetic evaluation of piperacillin-tazobactam

被引:69
|
作者
Hayashi, Yoshiro [2 ]
Roberts, Jason A. [1 ,3 ,4 ]
Paterson, David L. [2 ,5 ]
Lipman, Jeffrey [1 ,3 ]
机构
[1] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[2] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
[5] Royal Brisbane & Womens Hosp, Dept Infect Dis, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
beta-lactamases; pharmacodynamics; pharmacokinetics; piperacillin-tazobactam; Pseudomonas aeruginosa; INFECTIOUS-DISEASES-SOCIETY; CRITICALLY-ILL PATIENTS; IN-VITRO ACTIVITY; CONTINUOUS VENOVENOUS HEMOFILTRATION; SINGLE-DOSE PHARMACOKINETICS; BETA-LACTAM ANTIBIOTICS; INTENSIVE-CARE-UNIT; DOUBLE-BLIND; CONTINUOUS-INFUSION; ANTIMICROBIAL SUSCEPTIBILITY;
D O I
10.1517/17425255.2010.506187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous antibiotic for moderate to severe infections used in hospital settings because of its broad activity against many pathogenic bacteria including Pseudomonas aeruginosa. However, its pharmacokinetics (PK) can be significantly altered in a variety of states. Areas covered in this review: This article provides a comprehensive and critical review of the PK of piperacillin-tazobactam in different patient populations. The pharmacodynamics (PD) of piperacillin-tazobactam is also discussed. What the reader will gain: The importance of appropriate antibiotic dosing in the context of the global tendency for reduced susceptibility of bacteria, including P. aeruginosa is emphasized. The interrelationship between PK and PD is discussed to provide an understanding of methods for procuring dosing regimens that increase the likelihood of clinical success for individual patients. Alternative dosing regimens, which may include administration by extended or continuous infusion of piperacillin-tazobactam as a mechanism to increase the likelihood of pharmacodynamic target attainment, are described. Take home message: Where piperacillin-tazobactam is required for treatment, applying knowledge of PK and PD characteristics can facilitate optimal outcomes.
引用
收藏
页码:1017 / 1031
页数:15
相关论文
共 50 条
  • [41] False positive galactomannan Platelia due to piperacillin-tazobactam
    Gerlinger, M. P.
    Rousselot, P.
    Rigaudeau, S.
    Billon, C.
    Touratier, S.
    Castaigne, S.
    Eloy, O.
    MEDECINE ET MALADIES INFECTIEUSES, 2012, 42 (01): : 10 - 14
  • [42] Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy
    Wong, Jane C. Y.
    Au, Elaine Y. L.
    Yeung, Heather H. F.
    Lau, Chak-Sing
    Li, Philip Hei
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2021, 13 (02) : 284 - 294
  • [43] Evaluation of the safety of piperacillin-tazobactam extended infusion in pediatric cystic fibrosis patients
    Riggsbee, Daniel
    Engdahl, Samantha
    Pettit, Rebecca S.
    PEDIATRIC PULMONOLOGY, 2023, 58 (04) : 1092 - 1099
  • [44] EVALUATION OF PIPERACILLIN-TAZOBACTAM FOR ANTIBIOTIC PROPHYLAXIS IN TRAUMATIC GRADE 3 OPEN FRACTURES
    O'Connell, Casey
    Kooda, Kirstin
    Skrupky, Lee
    Mara, Kristin
    Wise, Kevin
    Sawyer, Mark
    CRITICAL CARE MEDICINE, 2020, 48
  • [45] Piperacillin-Tazobactam: Extended Infusion Versus Continuous Infusion
    Messori, Andrea
    Tulli, Giorgio
    Caccese, Erminia
    Trippoli, Sabrina
    Marinai, Claudio
    CRITICAL CARE MEDICINE, 2018, 46 (07) : E725 - E725
  • [46] Detection of galactomannan content in generic piperacillin-tazobactam products
    Saez de la Fuente, Javier
    Campelo-Gutierrez, Carolina
    Izquierdo-Garcia, Elsa
    Esteban, Aznar
    Jose Manuel, Caro
    Gimenez-Manzorro, Alvaro
    Garcia Diaz, Benito
    Becares, Javier
    INFECTIOUS DISEASES, 2019, 51 (02) : 157 - 159
  • [47] Galactomannan in piperacillin-tazobactam: How much and to what extent?
    Machetti, M
    Furfaro, E
    Viscoli, C
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3984 - 3985
  • [48] Piperacillin-tazobactam concentration target attainment in children with cancer
    Saffioti, Carolina
    Mesini, Alessio
    Barco, Sebastiano
    Cangemi, Giuliana
    Bandettini, Roberto
    Castagnola, Elio
    PEDIATRIC BLOOD & CANCER, 2019, 66 (10)
  • [49] Pharmacoeconomic analysis of extended-infusion piperacillin-tazobactam
    Raja, Karan
    Patel, Ruben
    Patel, Mitesh
    Attalla, Mark
    Philips, Mona
    PHARMACOTHERAPY, 2017, 37 (12): : E126 - E126
  • [50] Piperacillin-Tazobactam: An Unlikely Distractor In Invasive Aspergillosus Testing
    Dziamski, K. M.
    Gupta, K.
    Chandrasekar, V. Thoguluva
    Zaidi, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193